COHORT III: Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 14-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.